Loading chat...
NY A09152
Bill
Status
2/8/2024
Primary Sponsor
Amy Paulin
Click for details
AI Summary
-
Requires written notice from manufacturers, suppliers, and providers of non-invasive prenatal screening tests to accompany all such tests, clearly stating they are for screening purposes only and not for diagnosis.
-
Written notice must disclose that high-risk results do not always indicate abnormalities exist, low-risk results do not always mean abnormalities are absent, and positive results require confirmatory diagnostic testing.
-
Notice must be provided to patients before testing, with test results, and in all materials about prenatal testing services, be plainly worded and prominently displayed, and be approved by the Department of Health.
-
Requires the Department of Health to develop comprehensive informational materials about benefits and limitations of non-invasive prenatal testing, including current recommendations from ACOG, the Society for Maternal Fetal Medicine, and ACMG, to be posted online in multiple languages for distribution by hospitals and healthcare providers.
-
Effective 180 days after enactment; does not prevent healthcare practitioners from recommending prenatal testing based on professional judgment.
Legislative Description
Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities including the benefits and limitations of non-invasive prenatal testing, the difference between non-invasive prenatal testing and prenatal diagnostic testing, and current recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG).
Last Action
print number 9152a
4/4/2024